Leeds, UK, September 28, 2022 , – 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, announces that it will not report its interim results for the 6 months to 30 June 2022 by 30 September as required by Rule 18 of the AIM Rules for Companies (the “AIM Rules”).
This is a consequence of the Company having been placed into administration on 24 June 2022, when trading in the Company’s ordinary shares were suspended clarification of the Company’s financial position. Accordingly, the suspension will also remain in place pending announcement of the interim results in accordance with AIM Rule 18.
Further to the publication of the Joint Administrators’ Proposals on August 4 2022, the Joint Administrators continue to evaluate potential avenues to return the Company from administration and this process is ongoing. Further announcements will be made in due course.
Contact Information:
4D pharma
Singer Capital Markets – Nominated Adviser and Joint Broker
Philip Davies / James Fischer (Corporate Finance) +44 (0)20 7496 3000
About 4D pharma
4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease.  4D pharma has developed a proprietary platform, MicroRx®, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.
4D pharma’s Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. In addition to those programs listed above, there are two further clinical stage programs, namely Blautix® which is in development for the treatment of irritable bowel syndrome (IBS), and which has successfully completed a Phase II trial, and MRx0518 in patients with solid tumours, which successfully completed Part A as announced on 9 November 2020. Additional nonclinical-stage programs of LBPs include therapies for central nervous system (CNS) diseases, immune-inflammatory conditions and cancer. 4D pharma has a research collaboration with MSD (a tradename of Merck & Co., Inc., Kenilworth, NJ, USA), to discover and develop Live Biotherapeutics for vaccines.
